Trials / Completed
CompletedNCT04642079
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 839 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 15 Months – 17 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20vPnC | 20-valent pneumococcal conjugate vaccine |
Timeline
- Start date
- 2020-12-04
- Primary completion
- 2022-04-06
- Completion
- 2022-04-06
- First posted
- 2020-11-24
- Last updated
- 2024-01-22
- Results posted
- 2023-04-26
Locations
43 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04642079. Inclusion in this directory is not an endorsement.